Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22CART in Recurrent or Refractory B Cell Lymphomas
NCT06340737Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Mar 2024
- Primary completion
- Apr 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD22-CAR-T in follicular lymphoma (FL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL) and 4 more (4 cohorts), sponsored by Stanford University. Primary endpoints: Manufacturing Feasibility of CD22 CART at 6 years, Maximum Tolerated Dose / Recommended Phase 2 Dose at 6 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
CD22-CAR-T
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)hairy cell leukemia (HCL)Lymphoplasmacytic Lymphoma (LPL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT06340737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340737.